Spiral Therapeutics Completes $8.25M Financing and Initiates Phase 2 Trial in Ménière’s Disease

SOUTH SAN FRANCISCO, Calif., Jan. 9, 2023 /PRNewswire/ -- Spiral Therapeutics, Inc. ("Spiral"), a clinical-stage company focused on delivering therapies for inner ear disorders, today announced that the Company recently completed an $8.25M financing, with new proceeds that will fund the...

Click to view original post